Maravai Lifesciences Holdings, Inc. income statement

In fiscal 2025, Maravai Lifesciences Holdings, Inc. reported revenue of $186m, down 28.3% on the year before, operating income of −$215m (a -115.9% margin) and net income of −$131m, or −$0.90 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Maravai Lifesciences Holdings, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	143	284	799	883	289	259	186	209
Cost of revenue	67	80	141	169	149	151	152	136
Gross profit	76	204	659	714	140	108	34	73
Research and development	4	9	15	18	17	19	17	15
Selling, general and administrative	48	94	100	129	151	162	145	128
Operating income	24	120	555	574	−32	−236	−215	−117
Interest expense	30	31	30	20	46	48	27	24
Income before tax	−6	82	531	551	618	−261	−235	−136
Income tax	−1	3	62	61	756	−2	−4	−0
Net income	−4	89	182	220	−119	−145	−131	−77
Diluted EPS	−$0.06	$4.72	$3.12	$3.34	−$0.90	−$1.05	−$0.90	−$0.53
Diluted shares (average)	127m	14m	129m	128m	132m	138m	144m	146m
EBITDA	28	125	561	582	−19	−215	−192	−95

US$ millions unless shown otherwise. Fiscal quarters.

Maravai Lifesciences Holdings, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	69	57	47	47	42	50	66	51
Cost of revenue	37	37	39	40	36	37	32	31
Gross profit	32	19	8	8	6	13	34	21
Research and development	5	5	5	5	4	4	4	4
Selling, general and administrative	39	41	40	39	35	32	29	32
Operating income	−166	−38	−49	−66	−41	−59	−2	−15
Interest expense	14	11	7	7	7	7	6	5
Income before tax	−172	−46	−53	−74	−45	−63	−7	−22
Income tax	0	−0	0	−4	−0	0	−0	−0
Net income	−97	−26	−30	−40	−26	−36	−4	−12
Diluted EPS	−$0.68	−$0.18	−$0.21	−$0.27	−$0.18	−$0.24	−$0.02	−$0.08
EBITDA	−161	−32	−43	−60	−35	−53	3	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTKB vs MRVI CYRX vs MRVI MLAB vs MRVI MRVI vs SDGR

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Maravai Lifesciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Maravai Lifesciences Holdings, Inc.